Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

Garber, A. J., Foley, J. E., Banerji, M. A., Ebeling, P., Gudbjörnsdottir, S., Camisasca, R.‐P., Couturier, A., Baron, M. A. · 2008 · Diabetes, Obesity and Metabolism

Abstract

Aim: To compare the efficacy and tolerability of vildagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled [haemoglobin A 1c (HbA 1c ) 7.5 to 11%] with prior sulphonylurea (SU) monotherapy. Methods: This 24‐week, multicentre, randomized, double‐blind, placebo‐controlled study assessed the effects of the dipeptidyl peptidase‐4 inhibitor vildagliptin (50 mg given once or twice daily) vs. placebo added to glimepiride (4 mg once daily) in 515 patients with T2DM. Adjusted mean changes from baseline to end‐point (AMΔ) in HbA 1c , fasting plasma glucose, fasting lipids and body weight were compared by analysis of covariance. Results: The between‐group difference (vildagliptin − placebo) in AMΔ HbA 1c was −0.6 ± 0.1% in patients receiving vildagliptin 50 mg daily and −0.7 ± 0.1% in those receiving 100 mg daily (p < 0.001 vs. placebo for both). Greater efficacy was seen in patients ≥65 years of age (−0.7 ± 0.1% and −0.8 ± 0.2% for 50 and 100 mg daily respectively) and in patients with baseline HbA 1c > 9% (Δ = −1.0 ± 0.2% and −0.9 ± 0.2% for 50 and 100 mg daily respectively). Relative to placebo, patients receiving vildagliptin also had improvements in β‐cell function and postprandial glucose, with small changes in fasting lipids and body weight. The incidences of adverse events (AEs) (67.1, 66.3 and 64.2%) and serious AEs (2.9, 2.4 and 5.1%) were similar in patients receiving 50 mg vildagliptin, 100 mg vildagliptin or placebo respectively. The incidence of hypoglycaemic events was low but slightly higher in the group receiving vildagliptin 100 mg (3.6%) than in the group receiving vildagliptin 50 mg (1.2%) or placebo (0.6%). Conclusions: In patients with T2DM inadequately controlled with prior SU monotherapy, addition of vildagliptin (50 or 100 mg daily) to glimepiride (4 mg once daily) improves glycaemic control and is well tolerated. Addition of vildagliptin 50 mg daily to SU monotherapy may be a particularly attractive therapy in elderly patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00859.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 230

Metadata

Authors
Garber, A. J., Foley, J. E., Banerji, M. A., Ebeling, P., Gudbjörnsdottir, S., Camisasca, R. ‐., Couturier, A., & Baron, M. A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-10-14
Volume
10
Issue
11
Pages
1047-1056
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1969389642
Cited by
230
References
4
FWCI
24.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00859.x
The paper
Garber, A. J., Foley, J. E., Banerji, M. A., Ebeling, P., Gudbjörnsdottir, S., Camisasca, R. ‐., Couturier, A., & Baron, M. A. (2008). Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00859.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.